Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Current Liabilities Chart
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Total Current Liabilities
490.43
397.48
380.11
364.81
367.20
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of HK$367 Mil mean?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a Total Current Liabilities of HK$367 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Current Liabilities too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Total Current Liabilities is HK$367 Mil. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Current Liabilities compare to VRTX and REGN?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Current Liabilities of HK$367 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Total Current Liabilities is HK$367 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current Total Current Liabilities of HK$367 Mil. The current Total Current Liabilities is HK$367 Mil. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current Total Current Liabilities is HK$367 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score
Get the complete analysis for HKSE:02566
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02566 has been successfully added to your 
